Compare LITS & JFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LITS | JFU |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | China |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2M | 37.4M |
| IPO Year | N/A | 2018 |
| Metric | LITS | JFU |
|---|---|---|
| Price | $1.15 | $3.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 287.2K | 3.8K |
| Earning Date | 05-12-2026 | 12-09-2022 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.43 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $1.01 |
| 52 Week High | $3.03 | $9.48 |
| Indicator | LITS | JFU |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 41.22 |
| Support Level | $0.98 | $1.39 |
| Resistance Level | $1.16 | $4.91 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 39.13 | 19.08 |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.